Range Cancer Therapeutics ETF (CNCR)
| Assets | $13.56M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -1.32% |
| Volume | 7,680 |
| Open | 13.75 |
| Previous Close | 13.83 |
| Day's Range | 13.47 - 13.83 |
| 52-Week Low | 9.22 |
| 52-Week High | 15.18 |
| Beta | n/a |
| Holdings | 87 |
| Inception Date | Oct 13, 2015 |
About CNCR
Fund Home PageThe Range Cancer Therapeutics ETF (CNCR) is an exchange-traded fund that is based on the Range Cancer Therapeutics index. The fund tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products. CNCR was launched on Oct 13, 2015 and is issued by Range.
Top 10 Holdings
19.98% of assets| Name | Symbol | Weight |
|---|---|---|
| ImmunityBio, Inc. | IBRX | 2.58% |
| Revolution Medicines, Inc. | RVMD | 2.33% |
| Autolus Therapeutics plc | AUTL | 2.28% |
| MacroGenics, Inc. | MGNX | 2.17% |
| ImmunoGen, Inc. | IMGN | 1.90% |
| Blueprint Medicines Corporation | BPMC | 1.80% |
| Mirati Therapeutics, Inc. | MRTX | 1.79% |
| Arcellx, Inc. | ACLX | 1.76% |
| Fate Therapeutics, Inc. | FATE | 1.69% |
| Iovance Biotherapeutics, Inc. | IOVA | 1.69% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 29, 2021 | $1.85334 | Dec 31, 2021 |
| Dec 30, 2020 | $0.28812 | Jan 4, 2021 |
| Dec 28, 2017 | $0.3502 | Jan 2, 2018 |
| Dec 29, 2015 | $0.10551 | Jan 4, 2016 |
News
This Week in ETFs: 4 New Single-Stock Funds Debut
While the ETF industry didn't see over-the-top activity, the past week was fairly busy, with 11 new ETFs making their debut and six ETFs shutting down. Among the launches were two covered call funds f...
EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION
OKLAHOMA CITY , Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC, adviser to the Range Cancer Therapeutics ETF (CNCR) and the Loncar China BioPharma ETF (CHNA) is pleased to announce the co...
Last Week in ETFs: 15 Launches, Closures Continue Rapid Pace
It was a busy week for ETF launches and closures. A total of 15 ETFs launched during the week shortened by the Juneteenth holiday, defying the typically slow launch count for weeks surrounding three-d...
ALPS' Biotech ETF SBIO Week's Top Performer
In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way wit...
Should Investors Follow Private Equity into Life Sciences?
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...
Biotech ETFs extend January gains
Biotech exchange-traded funds rallied Monday as investors continued to monitor the sector and its impact on the coronavirus pandemic. The ETFMG Treatments Testing and Advancement ETF gained 4.6% mid-m...
As U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to Rally
Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. b...
Biotech ETFs Remain Hot As Investors Await Upcoming Vaccine
Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has...
Will Moderna Vaccine News Boost Biotech ETFs?
Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech,...
Specialty biotech funds jump on promising coronavirus, funding news
Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. Th...
Moderna Vaccine Optimism Could Drive Biotech ETFs
Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creat...
Moderna Study Sends Biotech ETFs And Stock Futures Surging
Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating...
AstraZeneca Joins Coronavirus Vaccine Race, Great For Biotech ETFs
With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.
3 ETFs For More Moderna Bets
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.
Biotech ETFs Climbing As Moderna Builds Hope For Coronavirus Vaccine
U.S. stocks are continuing to soar higher on Monday, moving into positive territory for May, following news that drugmaker Moderna released positive, preliminary results from the first human trial of ...
Biotech ETFs Strengthen as Amgen Invests in China’s BeiGene
Biotechnology company Amgen (NasdaqGS: AMGN) is throwing $2.7 billion into BeiGene (NasdaqGS: BGNE), sending the Chinese biotech’s shares surging and bolstering sector-related ETFs. Among the top perf...